LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Accueil・Liste d'Actions・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Fermé

SecteurSoins de santé

4.37 -6.02

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.34

Max

4.73

Chiffres clés
By Trading Economics
Revenu	36M -3.7M
Ventes	16M 66M
BPA	0.01
Marge bénéficiaire	-5.67
Employés	435
EBITDA	57M 15M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+3.43% upside

Dividendes
By Dow Jones
Prochains Résultats	10 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	350M 1.7B
Ouverture précédente	10.39
Clôture précédente	4.37

Sentiment de l'Actualité

By Acuity

50%

162 / 346 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

2.02 / 2.115 Support & Résistance

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 mai 2026, 22:54 UTC

Résultats

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13 mai 2026, 23:17 UTC

Résultats

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 mai 2026, 23:16 UTC

Résultats

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 mai 2026, 23:15 UTC

Résultats

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 mai 2026, 23:14 UTC

Résultats

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 mai 2026, 23:02 UTC

Market Talk

Résultats

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 mai 2026, 22:59 UTC

Market Talk

Résultats

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 mai 2026, 22:24 UTC

Résultats

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 mai 2026, 22:23 UTC

Résultats

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 mai 2026, 22:23 UTC

Résultats

Xero FY International Revenue Growth 47%>XRO.AU

13 mai 2026, 22:22 UTC

Résultats

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 mai 2026, 22:19 UTC

Résultats

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 mai 2026, 22:19 UTC

Résultats

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 mai 2026, 22:18 UTC

Résultats

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 mai 2026, 22:16 UTC

Résultats

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 mai 2026, 22:15 UTC

Résultats

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 mai 2026, 22:15 UTC

Résultats

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 mai 2026, 22:13 UTC

Résultats

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 mai 2026, 22:12 UTC

Résultats

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 mai 2026, 22:11 UTC

Résultats

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 mai 2026, 22:11 UTC

Résultats

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 mai 2026, 22:10 UTC

Résultats

Xero Did Not Declare a Dividend>XRO.AU

13 mai 2026, 22:10 UTC

Résultats

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 mai 2026, 22:09 UTC

Résultats

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 mai 2026, 22:00 UTC

Résultats

Cisco to Shed Jobs for All-In AI Push -- Update

13 mai 2026, 21:11 UTC

Résultats

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

3.43% hausse

Prévisions sur 12 Mois

Moyen 4.82 USD 3.43%

Haut 6 USD

Bas 3 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

Achat

Maintien

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

162 / 346Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.